Celgene Corporation (CELG)’s Fastest-Growing Drug

Other challenges for Istodax include competition, primarily from Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) . Spectrum picked up Folotyn, which is approved in the U.S. for PTCL, with its acquisition last year of Allos Therapeutics. The company also has a late-stage trial under way for belinostat targeting treatment of PTCL.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) could be a longer-term threat. The company is collaborating with Northwestern University on a phase 1 trial of carfilzomib in treating CTCL.

Looking ahead
Don’t look for Istodax to ever become the blockbuster that Revlimid is or that Vidaza and Abraxane probably will be. However, it wouldn’t be surprising to see the drug top $100 million in annual sales within the next couple of years. That’s not bad, but Istodax likely won’t grow to more than a small slice in Celgene’s revenue pie.

The article Celgene’s Fastest-Growing Drug originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.